December 13th 2024
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
October 14th 2024
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality Rates
March 11th 2020A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
Lower Risk of Melanoma Diagnosis and Increased Mortality Following Partner Bereavement
March 5th 2020These findings highlight the need to raise public awareness of the importance of self-skin examination, and to encourage clinicians to have a lower threshold for undertaking skin examinations in bereaved individuals, according to the researchers.
Poulikos Poulikakos, PhD, on Combining Targeted Therapy and Immunotherapy in Melanoma
November 26th 2019Poulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma
November 14th 2019Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?
September 3rd 2019A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
Diffuse Hepatic Infiltration by Metastatic Melanoma
Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20th 2019Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.